Arbutus Biopharma Reports Q2 2026 Financial Results

What Happened Arbutus Biopharma Corporation filed a Form 8-K on August 12, 2026 (Item 2.02) announcing its results of operations and financial condition for the quarter ended June 30, 2026. The company furnished a press release with those results as Exhibit 99.1, which is incorporated by reference into the filing. The Form 8-K was signed by Tuan Nguyen, Chief Financial Officer, on August 12, 2026.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026 results).
• Press release: Furnished as Exhibit 99.1 to the Form 8-K and incorporated by reference.
• Signature: Report signed by Tuan Nguyen, Chief Financial Officer, on behalf of Arbutus.

Why It Matters This 8-K notifies investors that Arbutus has publicly released its Q2 2026 quarterly results; the press release (Exhibit 99.1) is the primary source for detailed earnings, revenue, guidance, and other financial metrics. Retail investors should review the press release and any accompanying financial statements or investor materials to assess the company’s recent performance and any changes that could affect valuation or near-term trading decisions.